8/23/2012 9:21:40 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced the publication of a prospective, multicenter study of the Company’s CertNDx™ Bladder Cancer Assay for Hematuria Assessment in the online edition of Mayo Clinic Proceedings. The manuscript, entitled “A Noninvasive Multianalyte Urine-Based Diagnostic Assay for Urothelial Cancer of the Bladder in the Evaluation of Hematuria” will also appear in the upcoming September 6, 2012 print edition. The article can be accessed at Mayo Clinic Proceedings online.
comments powered by